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Abstract
Intravesical Bacillus Calmette-Guérin (BCG) has been shown to induce a specific immunologic response (i.e., activation of IL2 and effector T-cells), while preclinical studies using ALT-803 (mutated IL-15 analogue combined with IL-15Ra-Fc fusion)
have shown promising results by prolonging the agent’s half-life and stimulating CD8+ T-cells. Based on these results, we
hypothesized that the intravesical administration of ALT-803 along with BCG will generate an immunologic response
leading to significant bladder tumor burden reduction. Using a well-established carcinogen induced rat non-muscle invasive
bladder cancer (NMIBC) model, we studied the effects of intravesical ALT-803 with and without BCG. Rat tissues were
evaluated to document treatment response. Intravesical ALT-803 was safe and well tolerated alone and in combination with
BCG. As a single treatment agent, ALT-803 reduced tumor burden by 35% compared to control whereas BCG alone only
reduced tumor burden by 15%. However, the combination of ALT-803 plus BCG reduced tumor burden by 46% compared
to control. Immune monitoring suggested that the antitumor response was linked to the production and secretion of IL-1a,
IL-1b and RANTES, which in turn, induced the proliferation and activation of NK cells. Lastly, tumoral responses of the
combinational treatment were associated with 76% reduction in angiogenesis, which is significantly higher than when
assessed with either agent alone. The enhanced therapeutic index seen with this duplet provides justification for the
development of this regimen for future clinical trials.
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approximately 30% will progress and succumb to their disease
over a 15-year period, while another 50% will undergo radical
cystectomy in an attempt to control their disease [6]. As such, a
key issue in the field remains the need for better therapeutic
alternatives to reduce recurrence rates, improve survival rates and
obviate the need for radical surgery.
The exact mechanism of action by which intravesical BCG
exerts its anti-tumorigenic effects is not known. However, it is clear
that BCG activity is dependent on induction of inflammatory
responses involving activation of multiple types of immune cells.
Initially, intravesical BCG binds to the urothelial lining and is then
internalized and processed by normal and malignant cells which
trigger a complex proinflammatory response characterized by
release of IL-1, IL-6, IL-8, TNF-a and GM-CSF [7,8].
Subsequently, a variety of immune cells, including T cells, natural

Introduction
Bladder cancer (BCa) is the fifth most common malignancy in
the United States, to be diagnosed in approximately 74,690
patients resulting in approximately 15,580 deaths in 2014 [1].
Seventy to eighty percent of patients with BCa present with nonmuscle invasive bladder cancer (NMIBC), which is cancer
confined to the mucosa of the bladder [2,3]. NMIBC is treated
by transurethral resection of the tumors followed by the
administration of adjuvant intravesical chemotherapy or intravesical Bacillus Calmette-Guérin (BCG), which can decrease recurrence rates and prolong the progression-free interval [2–4].
Despite this, approximately 50–60% of NMIBC patients who
undergo resection and intravesical therapy will experience a tumor
recurrence [5]. Moreover, of those who experience a recurrence,
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killer (NK) cells, neutrophils, and macrophages migrate to the
bladder where they become activated and produce additional
proinflammatory cytokines and chemokines [9,10]. This is
characterized by the appearance of different leukocytes and
cytokines in the urine of BCG-treated patients. While the specific
role that various cell types and cytokines play in urothelial
carcinoma treatment is not completely clear, urinary Th1
cytokines (e.g., IFNc, IL-2, and IL-12) have been associated with
the BCG response, whereas high levels of Th2 cytokines (e.g., IL-10
and IL-6) correlate with BCG failure [9–16]. Overall, the ability of
intravesical BCG to interact with the urothelium and stimulate
broad, durable Th1- type immune responses is probably critical to
its efficacy. As a result, it has been suggested that the addition of
immunostimulatory agents, such as cytokines, to BCG therapy
could augment these immune responses and provide greater and/
or more durable antitumor effects. However, to date, phase 3
clinical investigations of intravesical BCG in combination with IL2 or IFN-a2b have been limited with only one trial reported,
which did not demonstrate benefit over BCG monotherapy [17].
Thus, optimal strategies for maximizing the immunotherapeutic
efficacy of intravesical treatment of NMIBC will likely require
novel approaches.
IL-15 is a critical factor in the development, proliferation and
activation of effector natural killer cells and CD8+ T cells [18,19]
and has been listed as the most promising agent among twelve
immunotherapy drugs with a high potential for use in treating
human cancers [20]. We have recently isolated a novel IL-15
mutant with a 4-fold increase in biological activity [21]. The
pharmacokinetics (PK), biodistribution and biological activity of
this IL-15 superagonist (IL-15N72D) have been further improved
through interaction with the soluble domain of the IL-15 receptor
a protein (IL-15RaSu) to create the IL-15N72D/IL-15RaSu-Fc
fusion complex (referred to as ALT-803). This complex has at least
25-times the in vivo biologic activity of native IL-15 [22,23]. We
have recently demonstrated that systemic ALT-803 treatment
induces durable and protective immune cell-mediated antitumor
responses in several mouse models for hematologic malignancies
[22,23]. ALT-803 stands out as a potent immunostimulant that is
capable of simultaneously activating the innate and adaptive arms
of the immune system to elicit both rapid and long-lasting
protective responses against infectious or neoplastic challenges to
the host [24].
Motivated by the compelling pre-clinical data related to IL-15,
we tested the therapeutic efficacy of intravesical ALT-803 alone
and in combination with BCG in a well-established rodent
carcinogen induced NMIBC model. Specifically, we observed that
a) intravesical ALT-803 was safe and well tolerated alone and in
combination with BCG, b) ALT-803 plus BCG reduced tumor
burden by 46% compared to control, which was higher than with
either agent alone, c) immune monitoring suggested that the
antitumor response seen with the combination of ALT-803 plus
BCG was linked to the production and secretion of IL-1a, IL-1b
and RANTES, which in turn, induced the proliferation and
activation of NK cells and d) tumoral responses seen with the
combination of ALT-803 and BCG were associated with a
significant reduction in angiogenesis. The encouraging results
presented in this report will support our consideration for further
development of this novel therapeutic duplet in the treatment of
patients with NMIBC.
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Materials and Methods
Animals, reagents, and tumor model
Ninety female Sprague Dawley rats, six to eight weeks old, were
obtained from Harlan Laboratories (Indianapolis, IN). Animal
care was in compliance with the recommendations of The Guide for
Care and Use of Laboratory Animals (National Research Council) and
approved by our local IACUC at the University of Central
Florida. N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) was purchased from TCI America (Portland, OR), aliquoted and dissolved
in 1% Tween. ALT-803 (IL-15N72D:IL-15RaSu/Fc) was generated as described previously [21] and diluted with sterile
phosphate buffered saline (PBS). PBS served as negative control.
Lyophilized BCG was purchased from Sanofi Pasteur Limited
(Toronto, CA) and reconstituted as per instructions with sterile
PBS and served as positive control. After allowing animals to
acclimate to our facility for one week, all animals except five
received 0.05% BBN in their drinking water continuously for eight
weeks inducing the formation of NMIBC, which is a wellestablished rodent carcinogen induced BCa model [25–30] with
marked molecular changes similar to human BCa [31]. After 8
weeks of BBN exposure, animals resumed water without the
addition of BBN.

Intravesical treatment
After BBN exposure (week 9), rats were randomized to one of
four treatment groups (control- PBS; ALT-803 at 1 mg/dose; BCG
at 1.35 mg/dose [26,27], or ALT-803 at 1 mg/dose plus BCG
1.35 mg/dose). Each group contained 20 animals. Preliminary
experiments with ALT-803 noted a) therapeutic response with an
intravesical dose of 1 mg and b) improved therapeutic response
with the concomitant administration of ALT-803 plus BCG
compared to the sequential administration of these two agents
(data not shown). All bladder instillations were done in 200 ml of
sterile PBS. Rats were anesthetized with isoflurane then a 22gauge Teflon angiocatheter (transurethral catheter) was placed
into the bladder via the urethra and urine was completely drained
from the bladder [32]. Next, PBS, BCG, ALT-803, or combination of ALT-803 plus BCG therapy was delivered by transurethral
instillation through the transurethral catheter and allowed to dwell
in the bladder for 1 hour by occlusion of the urethra with a purse
string suture. After 1 hour, the purse string suture was removed
and rats were stimulated to expel bladder contents [32]. The
intravesical therapy was administered weekly for a total of six
weeks to mimic intravesical BCG therapy in humans [33]. Two
weeks after completion of the intravesical therapy, animals were
sacrificed and tissues (e.g., whole blood, serum, urine, bladder and
spleen) were harvested and processed for subsequent analysis.
Figure 1 illustrates the study treatment schema.

Ultrasound imaging studies
Throughout the study, intravesical tumor burden was monitored in situ by transabdominal ultrasound imaging using the Vevo
2100 imaging system with a MS550D 22–55 MHz hand held
MicroScan array transducer (Visualsonics, Toronto, ON, Canada). Briefly, rats were anesthetized with isoflurane then 200 ml of
sterile PBS was instilled into the bladder as described above to
provide a uniform image of all bladders visualized. Intraluminal
tumors were observed and digital images captured. Bladder wall
thickness (in millimeters), a surrogate of tumor burden, was
measured with the Vevo 2100 measurement feature.

2

June 2014 | Volume 9 | Issue 6 | e96705

IL-15 in the Treatment of Bladder Cancer

Figure 1. Study treatment schema. Treatment with PBS, BCG, ALT-803, or ALT-803 plus BCG commenced one week after completion of the eight
weeks exposure to 0.05% N-butyl-N-(4- hydroxybutyl) nitrosamine in drinking water. Rats were randomly assigned into four groups and treated
weekly for six consecutive weeks according to the schedule. Rats were sacrificed and necropsied two weeks later. CTRL, control.
doi:10.1371/journal.pone.0096705.g001

monoclonal antibody, dilution 1/1 500). Frozen sections were
incubated overnight with antibodies against CD4+ (BD Biosciences; OX-35; mouse monoclonal antibody, dilution 1/250) or CD31
(Santa Cruz Biotechnology; H3; mouse monoclonal antibody,
dilution 1/250). Next, the deparaffinized and frozen sections were
incubated with biotinylated anti-mouse or anti-rabbit IgG (H+L)
antibodies at 10 mg/ml (Vector Laboratories INC., Burlingame,
CA). Subsequently, sections were stained using the Ultra-Sensitive
ABC Mouse IgG staining kit (EMD Millipore, Billerica, MA) or
the Biotin/Streptavidin immunostaining kit (Fisher Scientific,
Pittsburgh, PA). All stained sections were imaged using a Nikon
Eclipse E400 light microscope (Nikon Inc., Melville, NY) with the
QIClick digital CCD camera (QImaging, Surrey, BC, Canada)
and the Nikon NIE-Elements Basic Research imaging software.
Detailed histopathologic analysis of the neoplastic response to
intravesical therapy was performed in each bladder by two
experienced, independent observers (MM and AS). Briefly, CD3+,
CD4+, CD8a+ T-cells, NK cells and macrophages were counted in
a minimum of four randomly selected fields per high power field
(hpf) in each specimen. Results were scored by calculating the
number of infiltrating immunostaining cells.
Furthermore, tumor angiogenesis was investigated on slides
stained with anti-CD-31 monoclonal antibody and microvessel
density (MVD, microvessel/mm2) was assessed as previously
described by Weidner et al. [34]. Single endothelial cells or
clusters of endothelial cells positive for CD-31 were considered as a
vessel. Four areas with the highest microvessel concentration from
each specimen were identified at 46 magnification and images
were taken for quantitation of MVD at 2006. The two
independent observers counted the number of microvessels in

Histopathology of tumor sections
Resected bladders were initially weighed then 12 bladders from
each group were filled with 200 ml of 10% neutral buffered
formalin. The bladder necks were ligated and the entire specimens
placed in 10% neutral buffered formalin. Bladders in formalin
were embedded in paraffin, sectioned (5 mm) and placed on
Superfrost plus Micro slides (Fisher Scientific, Pittsburgh, PA). The
remaining eight bladders in each group were filled with 200 ml of
O.C.T. embedding compound (Andwin Scientific, Schaumburg,
IL) and the bladder necks were ligated. The bladders were
submersed in Tissue-Tek O.C.T. compound (Ted Pella, Inc.,
Redding, CA) in cryomolds and frozen in liquid nitrogen and
stored at 280uC. Bladders frozen in O.C.T. were sectioned
(5 mm), warmed at room temperature for 5 minutes, fixed in icecold methanol for 10 minutes, and washed with PBS prior to
immunohistochemical staining. Deparaffinized and frozen sections
from each rat were subjected to hematoxylin and eosin stain for
histological evaluation. Additionally, deparaffinized slides were
treated with 1% hydrogen peroxide in 100% methanol to block
endogenous peroxidase activity followed by citric acid antigen
retrieval. Slides were incubated overnight with antibodies against
CD3+ (BD Biosciences; G4.18; mouse monoclonal antibody,
dilution 1/250), CD8a+ (BD Biosciences; OX-8; mouse monoclonal antibody, dilution 1/10), CD161+ (AbDSerotec; 10/78; mouse
monoclonal antibody, dilution 1/100) (detecting NK cells),
CD163+ (AbDSerotec; ED2; mouse monoclonal antibody, dilution
1/50) (detecting macrophages), Ki-67 (Dakota North America
Inc.; MIB-5; mouse monoclonal antibody, dilution 1/50), or
cleaved caspase 3 (Cell Signaling Technology; 5A1E; rabbit
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each histological field. MVD of the specimen was estimated as a
mean of vessels in at least four histological fields. In addition,
staining slides with the monoclonal antibody directed against Ki67 assessed proliferation. Ki-67 immunostaining was counted in a
minimum of four randomly selected fields from each treatment
group at 2006 magnification. Cells with questionable nuclear
staining were discounted. The observers scored the results by
estimating the percentage of tumor cells showing the characteristic
nuclear staining (proliferative index). Lastly, staining slides with
the monoclonal antibody directed against cleaved caspase-3
assessed apoptosis. Cleaved caspase-3 immunostaining was counted in a minimal of 3,000 cells from each treatment group at 2006
magnification. The two observers scored the results by estimating
the percentage of tumor cells showing the characteristic cellular
staining (apoptotic index).

Statistics
Experimental data were expressed as mean 6 SEM, unless
otherwise indicated. Statistical analysis was conducted using nonparametric Kraskal-Wallis test followed by post-hoc Dunnet’s test
for bladder weight, bladder wall thickness, immunostaining of the
bladder, urinary cytokines and serum cytokines. Parametric
ANOVA test followed by post-hoc Bonferroni’s test was performed
for the data related to lymphocytes within spleen and lymphocytes
within the peripheral blood. A p,0.05 was considered significant.
All statistical analyses and figures were carried out using
GraphPad Prism software 5.0 (GraphPad Software, Inc., La Jolla,
CA).

Results
Antitumor activity of BCG, ALT-803 and ALT-803 plus
BCG in NMIBC-bearing rats

Flow cytometric analysis of PMBC and spleen for T-cells,
NK cells and Macrophages

In a rodent carcinogen induced NMIBC model, routine
monitoring of tumors was performed by serial ultrasound imaging
with the Vevo 1200 system. Tumors were detectable as early as 3
weeks after exposure to 0.05% N-butyl-N-(4-hydroxybutyl) nitrosamine in drinking water. As demonstrated by ultrasound imaging
and confirmed on histologic examination, 100% of animals were
found to develop tumors. No animals had palpable, advanced
tumors. To determine if ultrasound imaging could be used to
monitor and assess tumor burden, bladders were imaged and
bladder wall thickness (a surrogate for tumor burden reported in
millimeters) was determined. Subsequently bladders were resected,
weighed and histopathologically examined. We noted a positive
correlation (Spearman R = 0.55, p,0.0001) between bladder wall
thickness and bladder weights/bladder tumor, thus we report for
the first time that the non-invasive in situ monitoring of rodent’s
bladder tumor may be used to a) confirm tumor take and b) report
therapeutic tumor-burden reduction.
Rats bearing bladder tumors were treated intravesically for 6
consecutive weeks with PBS, BCG, ALT-803 or ALT-803 plus
BCG. Other than the scant hematuria noted (perhaps from
catheterization and/or BCG), intravesical therapies were well
tolerated with no appreciable toxicities noted.
Consistent with the development of in situ tumors, bladder
weights increased by 49% in animals receiving BBN when
compared to normal (no BBN) control animals (data not shown).
However after six weeks of intravesical therapy with BCG, ALT803 or ALT-803 plus BCG significantly decreased the tumor
burden in bladders of the BBN-treated rats (Fig. 2). Bladder
weight (mean+/2SEM) was reported to be: PBS- 0.2+/2
0.012 grams, BCG- 0.17+/20.012 grams, ALT-803- 0.15+/2
0.0091 grams and ALT-803 plus BCG- 0.14+/20.0054 grams. In
addition prior to being sacrifice at week 16, 200 ml of sterile PBS
was instilled into each bladder to ensure uniformity in size and a
series of transverse and sagittal ultrasound images were obtained.
Bladder wall thickness (mean+/2SEM) was reported to be: PBS1+/20.11 mm, BCG- 0.7+/20.05 mm, ALT-803- 0.65+/2
0.077 mm and ALT-803 plus BCG- 0.54+/20.083 mm. Thus
from these images, we noted with BCG treatment a 30% reduction
in mean bladder wall thickness, which corresponded to a 15%
reduction in bladder weight change compared to PBS treatment.
ALT-803 treatment alone was noted to have a 25% reduction in
mean bladder wall thickness and a corresponding 35% reduction
in bladder weight change when compared to PBS treatment.
Interestingly, the greatest reduction in bladder wall thickness and
bladder weight was seen when ALT-803 was combined with BCG
leading to a 30% reduction in bladder wall thickness and a
corresponding 46% reduction in bladder weight change compared

Rat peripheral blood mononuclear cells collected from whole
blood samples in EDTA tubes were stained directly by incubation
with fluorescently labeled antibodies CD3+ (eBioscience), CD4+
(BD Biosciences), CD8a+ (eBioscience), NKG2D-positive
(eBioscience) (detecting NK cells), F480-PE (eBioscience) (detecting macrophages), or isotype control antibodies (eBiosciences, San
Diego, CA) for 30 minutes at room temperature, followed by red
blood cell lysis using BD FACS Lysing Solution (BD Biosciences,
San Jose, CA) at room temperature for 3–5 minutes. Cells were
subsequently washed twice with PBS containing 1% fetal bovine
serum. Stained cells were analyzed using a FACScan flow
cytometer (BD Biosciences) and data were collected for 10,000
events/sample. Analysis of the data collected was performed using
Cyflogic software (CyFlo LTD, Turku, Finland). In addition,
single cell suspensions of the rats’ spleens were generated by gently
homogenizing tissue in a petri dish and then passing through a
Cellector Tissue Sieve (Bellco Glass, Vineland, NJ). Red blood
cells were removed from rat splenocytes with BD FACS Lysing
Solution by incubation for 3–5 minutes at room temperature,
followed by centrifugation at 1,200 rpm for 5 minutes. The
pelleted splenocytes were washed twice with PBS containing 1%
fetal bovine serum followed by direct immunofluorescence staining
as described above.

Urinary and serum inflammatory cytokine ELISA assay
Voided urine from each rat was collected in a tube on ice
containing a concentrated urine stabilizer solution (2 M Tris-HCl
[pH 7.6], 5% BSA, 0.1% sodium azide, and a COMPLETE mini
protease inhibitor tablet (Roche Diagnostics, Indianapolis, IN)).
Urine was centrifuged and supernatant was stored at 280uC.
Similarly, serum was collected in tubes containing EDTA,
centrifuged at 10,0006g for 15 minutes, and stored at 220uC.
Urine and serum samples were subjected to profiling of 12
inflammatory cytokines using an ELISA assay (RAT Cytokine
multi-analyte ELISArray, SABiosciences, San Diego, CA). Briefly,
urine and serum samples were incubated in 96-well microplates
coated with anti-rat primary antibodies against 12 inflammatory
cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13,
IFN-c, TNF-a, GM-CSF, and RANTES) and then developed
with secondary antibodies conjugated with horseradish peroxidase.
After adding the substrate and stop solution, a FLUOstar Optima
Reader (BMG LABTECH, Ortenberg, Germany) was used to
measure absorbance at 450 nm.
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to PBS treatment (Fig. 2a–2c). All results were subsequently
confirmed by detailed histologic examination (Fig. 2d) in which
H&E-stained sections were microscopically examined and classified as (a) normal urothelial mucosa characterized by epithelium of
less than three layers without any dysplasia or (b) urothelial
carcinoma [29].

to ALT-803 alone, but when compared to BCG alone, the number
of infiltrating CD3+ T-cells was significantly higher in the
combination group. CD4+ T- cells were not affected in any group
compared to PBS (data not shown). CD8a+ T-cells were significantly
increased in BCG alone, ALT-803 alone and ALT-803 plus BCG
compared to PBS. The combination of ALT-803 and BCG did
not have a larger effect than BCG alone or ALT-803 alone. Next,
the number of NK cells was not increased in BCG alone or ALT803 alone compared to PBS, but the number of NK cells was
increased when ALT-803 was added to BCG. Furthermore, the
combination of ALT-803 plus BCG resulted in increased
infiltrating NK cells compared to BCG alone or ALT-803 alone.
No significantly changes in macrophage infiltration were observed
in any treatment group.

Intravesical ALT-803 plus BCG promotes a unique
lymphocytic infiltration
The bladders of treated rats were also stained for immune cell
(CD3+, CD4+, CD8a+ T-cells, NK cells and macrophages)
infiltrates (Fig. 3 and Table S1). The number of CD3+ T-cells
was significantly increased in ALT-803 alone compared to PBS
and BCG alone. Combination of ALT-803 plus BCG did not
improve upon the number of infiltrating CD3+ T-cells compared

Figure 2. Antitumor activity of BCG, ALT-803 and ALT-803 plus BCG. NMIBC were induced in female Sprague Dawley rats by the exposure to
0.05% N-butyl-N-(4-hydroxybutyl) nitrosamine in drinking water. At week 9, rats were randomized to one of four treatment groups (PBS, BCG, ALT803, or ALT-803 plus BCG). Each group received weekly intravesical therapy for six consecutive weeks. On week 16, rats were sacrificed. A) Prior to
bladder resection, 200 ml of sterile PBS was instilled into bladder and imaging of the bladder was performed with the Vevo 2100 Ultrasound System
from VISUALSONICS (22–55 MHz probe). Thickness of the bladder wall was recorded in millimeters. Non-parametric Kraskal-Wallis test followed by
post-hoc Dunnet’s test was performed. Representative images from the four groups (top left) along with mean bladder wall thickness (top right) are
illustrated. B) Resected bladders were fixed in 10% buffered formalin and embedded in paraffin and subsequently stained with hematoxylin and
eosin. Detailed histopathologic examination of each bladder was performed to assess tumor burden. Representative images from the four groups are
illustrated. The greatest reduction in bladder tumor burden was seen in ALT-803 and ALT-803 plus BCG. C) Bladder wall thickness was reduced in
groups treated with ALT-803, BCG and ALT-803 plus BCG compared to control. Greatest reduction in bladder wall thickness was seen in the group
treated with ALT-803 and ALT-803 plus BCG (p = 0.0001). D) Bladder weight was reduced in groups treated with BCG alone, ALT-803 alone and ALT803 plus BCG compared to control. Greatest reduction in bladder weight was seen in the group treated with ALT-803 plus BCG. *, p,0.05, **, p,0.01,
***, p,0.001.
doi:10.1371/journal.pone.0096705.g002
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Figure 3. Treatment-related changes in key lymphocytic cell tumoral infiltration. Tumoral infiltration of cells positive for CD3+, CD8a+,
CD161 (NK cell), or CD163 (macrophage) (2006) were noted. No changes were noted in CD4+ T-cells (data not shown). ALT-803 alone increased
tumoral CD8a+ expressing cells, whereas ALT-803 plus BCG increased tumoral expression of NK cells (See Table S1). Insert, left panel positive control
from rat spleen and right panel negative control from rat spleen without primary antibody.
doi:10.1371/journal.pone.0096705.g003

baseline when ALT-803 was added to BCG (Fig. 4b). These data
provide compelling evidence that the combination of ALT-803
plus BCG is associated with the stimulation of NKG2D-positive
cells, which was likely the effector cell mediating tumor regression
during intravesical combination immunotherapy.

PBMC in whole blood from rats treated on this protocol was
collected immediately after the animals were sacrificed and
subjected to flow cytometric analysis for the presence of CD3+,
CD4+, CD8a+ T-cells, NKG2D-positive cells and macrophages.
No appreciable changes were noted for CD3+ and CD4+ T-cells,
while CD8a+ T-cells were noted to be significantly elevated only in
BCG alone group. All groups (BCG alone, ALT-803 alone and
ALT-803 plus BCG) demonstrated a significant increase in
NKG2D-positive cells compared to control. Lastly, the number
of circulating macrophages was significantly reduced in ALT-803
alone and ALT-803 plus BCG, but not in BCG alone (Fig. 4a).
Similar results were obtained from the analysis of the rat splenic
tissues. Specifically, no appreciable changes were noted with
CD3+, CD4+ and CD8a+ T-cells amongst the treatment groups.
However, the number of NKG2D-positive cells was significantly
increased in the spleens from rats in all groups (BCG, ALT-803
and ALT-803 plus BCG) compared to control. Combination of
ALT-803 plus BCG did not note an increase in the number of
NKG2D-positive cells compared to BCG alone or ALT-803 alone.
Furthermore, the number of macrophages within the spleen was
significantly reduced in ALT-803 alone when it was compared to
PBS and BCG alone. The number of macrophages returned to

PLOS ONE | www.plosone.org

Intravesical administration of ALT-803 plus BCG
facilitated unique cytokine profile
Sera from rats treated on this protocol were collected and
immediately stored at 280uC. For the cytokine analysis, sera
samples were thawed and then subjected to analysis with the rat
inflammatory cytokines multi-analyte ELISArray assay. Along
with proliferation and activation of NK cells noted above, the
intravesical administration of ALT-803 in combination with BCG
was associated with increased serum levels of the inflammatory
and immune response cytokines, IL-1a and IL-1b by 52% and
52%, respectively, compared to that of the PBS control group.
Furthermore, the increase in IL-1a and IL-1b was maintained
when ALT-803 plus BCG was compared to BCG alone and ALT803 alone (Fig. 5a). Next, urine from rats treated on this protocol
were collected and stored at 280uC immediately after the animals
were sacrificed. When ready for analysis, urine samples were
6
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Figure 4. Treatment-related activation of peripheral immune cells in female rats with carcinogen induced NMIBC. A) Peripheral blood
mononuclear cells (PBMC) were isolated and analyzed by flow cytometry for expression of CD3+, CD4+, CD8a+ T-cells, NKG2D- positive (NK cells) and
F480 expression cells (macrophages). ALT-803 alone, as well as, ALT- 803 plus BCG resulted in an increase in NKG2D-positive cells and a decrease in
macrophages compared to PBS. B) Splenocytes were isolated and analyzed by flow cytometry for expression of CD3+, CD4+, CD8+, NKG2D-positive
and F480 expression cells. Similar to the PBMC results, ALT-803 alone, as well as, ALT-803 plus BCG resulted in an increase in NKG2D- positive cells and
a decrease in macrophages compared to PBS. *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0096705.g004

1.66 in the BCG alone group, by 3.86 in the ALT-803 alone
group and by 7.76 in the ALT-803 plus BCG group.

thawed and subjected to the rat inflammatory cytokines multianalyte ELISArray assay. Once again, the cytokines, IL-1a, IL-1b
and RANTES were increased by 437%, 437% and 196%,
respectively, in the urine of the ALT-803 plus BCG treated rats
compared to the PBS control group. Nevertheless, BCG alone and
ALT-803 alone were associated with increases in IL-1a, IL-1b.
Only RANTES was significantly elevated in ALT-803 plus BCG
when compared to BCG alone and ALT-803 alone (Fig. 5b).
Within the serum, IL-1a and IL-1b are key cytokines, while locally
RANTES is the key cytokine.

Discussion
As previously described, the IL-15N72D mutein was generated
through site-directed mutagenesis of IL-15 wild type and found to
exhibit super agonist activity through improved interactions with
the human IL-15Rb chain [21]. The IL-15N72D mutein
displayed ,4 fold lower effective concentration (EC50) than wildtype IL-15 and the super agonist activity was enhanced further by
pre-association with either mouse or human IL-15Ra-Fc molecules [21,22]. Overall, the IL-15N72D/IL-15Ra-Fc (ALT-803)
complex exhibited a 25-fold lower EC50 than IL-15 alone for
supporting IL-15-dependent cell growth, indicating the complex
provides highly potent biological activity. The enhanced activity of
the IL-15N72D/IL-15Ra-Fc complex is likely the result of a
combination of the increased binding activity of the N72D mutein
to the IL-2Rbc complex, optimized cytokine trans-presentation by
the IL-15Ra chain, the dimeric nature of the cytokine domain and
its increased in vivo half-life compared to native IL-15 [35,36].
Recently, Xu et al. reported on the therapeutic efficacy of
intravenous ALT-803 in a myeloma xenograft model and alluded
to the possible mechanism behind ALT-803 activity [23]. Briefly, a
single dose of ALT-803, but not IL-15 alone, eliminated wellestablished 5T33P and MOPC-315P myeloma cells from the bone
marrow of tumor-bearing mice and prolonged survival in
myeloma-bearing mice. ALT-803 treatment stimulated CD8 cells
to secrete IFN-c and promoted rapid expansion of CD8(+
)CD44(high) memory T-cells. These memory CD8(+) T- cells also
exhibited nonspecific cytotoxicity against myeloma and other

Comparison of bladder tumor proliferation, apoptosis
and angiogenesis following intravesical therapy
We believe the primary mode of action for ALT-803 and BCG
is the result of this duplet’s ability to stimulate the secretion of IL1a, IL-1b and RANTES, which led to the activation and
infiltration of NK cells. However, we also sought to determine if
these cytokines affected key tumoral processes (e.g., angiogenesis,
proliferation and apoptosis) (Fig. 6). First, we set out to assess the
angiogenic potential within each group by reporting the MVD.
MVD was significantly reduced by 40% in the BCG alone group,
59% in the ALT-803 alone group and by 76% in the ALT-803
plus BCG group. Next, counting the number of Ki-67 expressing
cells per hpf assessed the proliferative index. Compared to control,
we noted a 40% reduction of the proliferative index in the BCG
alone group, 52% reduction in the ALT-803 alone group and 80%
reduction in the ALT-803 plus BCG group. Finally, the number of
cleaved caspase-3 positive cells per hpf was measured to derive an
apoptotic index. Compared to control, apoptosis was increased by
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Figure 5. Changes in serum and urinary cytokine profiles following intravesical treatment. A) Serum cytokines - Serum samples from
female rats with carcinogen induced NMIBC was compared among the four treatment groups. Serum levels of a panel of cytokines were measured by
Rat Inflammatory Cytokines Multi-Analyte ELISArray Kit (SABiosciences, Valencia CA). Mean 6 SEM of each cytokine is reported for each treatment
group. B) Urinary cytokines - Voided urine samples from female rats with carcinogen induced NMIBC was compared among the four treatment
groups. Rat Inflammatory Cytokines Multi-Analyte ELISArray Kit measured urine levels of a panel of cytokines. Mean 6 SEM of each cytokine is
reported for each treatment group. *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0096705.g005

proliferation of NK cells, which led to the significant reduction
in tumor burden. Interestingly, ALT-803 alone resulted in similar
tumor reduction and production of urinary IL-1a, IL-1b and
RANTES, which also led to the activation and proliferation of
CD8a+ T-cells. However, the reduction in angiogenesis was
significantly enhanced when ALT-803 was combined with BCG
compared to ALT-803 alone. Specifically, tumoral responses to
the combinational therapy were associated with 76% reduction in
angiogenesis compared to only a 40% and 59% reduction in
angiogenesis in BCG alone and ALT-803 alone groups, respectively. Furthermore, there was a trend that ALT-803 plus BCG
resulted in reduced rates of cellular proliferation and increased
rates of apoptosis compared to PBS or either agent alone. Thus,
we believe if tumors were assessed at later time points that a
greater reduction in tumor burden may be evident in ALT-803
plus BCG compared to ALT-803 alone. Our results provide strong
evidence for ALT-803 as a viable and promising therapeutic agent
against NMIBC. Herein, we present significant findings for the
antitumor activity of ALT-803 in combination with the standard
therapeutic modality for BCa treatment, BCG. Our results show
representative reductions in tumor burden. Additionally, ALT-803
plus BCG therapy was noted to stimulate the production and
secretion of key cytokines, IL-1a, IL-1b and RANTES, which in
turn, induced the proliferation and activation of NK cells.

tumor cells in vitro, whereas IFN-c had no direct effect on myeloma
cell growth in vitro. Though ALT-803 lost its antimyeloma activity
in tumor-bearing IFN-c knockout mice, it was able to retain its
ability to promote CD8(+)CD44(high) memory T-cell proliferation, indicating that ALT-803-mediated stimulation of CD8(+
)CD44(high) memory T-cells is IFN-c-independent [23]. ALT-803
stands out as a potent immunostimulant that is capable of
simultaneously activating the innate and adaptive arms of the
immune system to elicit both rapid and long-lasting protective
responses against infectious or neoplastic challenges to the host
[24]. Thus, we hypothesize that intravesical administration of
ALT-803 plus BCG will provide durable and potent cell-mediated
immune responses, which would result in a highly efficacious and
potentially curative immunotherapy for patients with NMIBC.
In the current study, we confirmed that ALT-803 stimulated
CD8+ T-cells proliferation. Unlike in the study by Xu et al. [23],
we did not note an increase in IFN-c levels associated with the
proliferation of CD8a+ T-cells, but this could be due to the fact
that we did not assess cytokine levels until two weeks after the last
dose of ALT-803 was administered. Thus, IFN-c production may
be a more immediate response to IL-15 stimulation. The novelty
of our study is that the combination of ALT-803 plus BCG
stimulated the production of key sera and urinary cytokines (e.g.,
IL-1a, IL-1b and RANTES) leading to the activation and
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Figure 6. Treatment-related changes in key biomarkers in bladders of female rats with carcinogen induced NMIBC. Analysis of
bladder angiogenesis (MVD), proliferation index (PI) and apoptosis index (AI) by IHC (2006) as described in the Material and Methods. *, p,compared
to PBS; #, p,0.05 compared to BCG, `, p,0.05 compared to ALT-803.
doi:10.1371/journal.pone.0096705.g006

regimen were consistent with the observed effects of IL-15 on the
host immune system when IL-15 was administrated intravenously
[45].
Adjuvant intravesical BCG treatment has proven to be superior
to other agents in the management of NMIBC and is the most
commonly prescribed therapeutic agent for this population [46].
In addition, the use of maintenance intravesical BCG after
induction BCG therapy was previously shown to be superior
compared to no maintenance BCG [47]. In fact, current
guidelines recommend the use of induction and maintenance
BCG in patients with intermediate and high risk NMIBC [2–4].
However, although BCG treatment has been shown to delay
tumor progression and improve overall survival, its efficacious is
limited to early stage disease and up to 50–60% of patients fail
BCG therapy and recur [5]. BCG is a nonspecific immune
stimulant that evokes a complex immune response in the bladder,
beginning with its binding to fibronectin and integrin-mediated
internalization by urothelial cells followed by expression of various
pro-inflammatory cytokines [48]. This, in turn, induces recruitment and activation of immune effector cells resulting in improved
recognition and killing of the tumor by both non-specific and
specific mechanisms.

Previous studies have reported that IL-15 can induce CD8+ Tcells [23,37], NK cells [38], and macrophages [39]. Using ALT803, we were also able to demonstrate an induction in CD8a+ Tcells, which also occurred with the administration of BCG. The
activation of CD8+ T- cells by intravesical BCG administration
has been previously reported [40]. We observed the activation and
proliferation of NK cells in the peripheral blood and spleen of
animals treated with ALT-803 plus BCG. This was associated with
an antitumor response and a marked increase in infiltrating NK
cells within the bladder along with secretion of factors involved in
inflammatory and immune responses. Among the locally elevated
immune factors triggered by the combination of ALT-803 and
BCG treatment within the bladder included IL-1a and IL-1b,
which are both secreted by activated macrophages and neutrophils
and are known to play major roles in the initiation and regulation
of inflammation [41]. BCG has previously been linked to the upregulation of IL-1a and IL-1b [42]. More importantly, RANTES
was significantly increased in both the serum and urine in rats
treated with ALT-803 plus BCG. RANTES is expressed and
secreted by T-cells and promotes antitumor immunity by
recruitment and activation of NK cells [43] and has been linked
to IL-15 [44]. These induced immune responses observed
following the intravesical treatment with ALT-803 plus BCG
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Recent studies suggest IL-15 may stimulate effective antitumor
responses in a variety of cancers, including BCa [49–51]. In one
study by Matsumoto et al., IL-15 gene therapy resulted in a marked
inflammatory response with infiltration of CD8+ T-cells in the
vicinity of mouse bladder tumors. The investigators also confirmed
an inhibition in growth of a subcutaneous MBT-2 murine BCa
cells as a result of tumor-specific cytotoxic T lymphocyte
recruitment [51]. Obviously gene therapy has significant limitations, which may prohibit it from successfully advancing into
clinical trial [52], whereas ALT-803 has a negligible toxicity thus
making it more likely to move towards an early phase clinical trial.
No new agent has been FDA approved for the treatment of
NMIBC since 1998 [53]. Better therapeutic alternatives are
desperately needed for patients suffering from NMIBC. With its
ability to activate NK cell responses and support T memory cell
proliferation, IL-15-based therapies would be expected to further
augment the antitumor activity of BCG, consistent with the results
with ALT-803 plus BGC shown in this study. Indeed, improved
clinical therapies may rely on the intravesical combination of
traditional agents (i.e., BCG) with novel compounds (i.e., ALT803).

resulted in only an incremental gain in treatment success. Thus
there is universal agreement that better therapeutic strategies are
needed for patients with NMIBC to improve disease specific
survival and obviate the need for radical extirpative surgery such
as cystectomy. In this study, we have clearly demonstrated the
therapeutic activity of ALT-803 plus BCG in NMIBC. Specifically, we found ALT-803 plus BCG to be superior to intravesical
BCG alone or ALT-803 alone not only in terms of tumor burden
reduction, but also in local cytokine production and secretion, as
well as activation and proliferation of NK cells. As a result, clinical
investigation of intravesical ALT-803 plus BCG as a treatment
regimen for NMIBC is highly warranted.
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Conclusions
While BCa may be initially sensitive to chemotherapy and
BCG, recurrence may develop and thus current regimens have
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